Fierce Biotech January 12, 2024
Conor Hale

The FDA has granted a de novo clearance to an artificial intelligence program capable of reading a standard brain MRI scan and predicting a patient’s chances of progressing from mild cognitive impairment and early memory loss to Alzheimer’s disease and dementia within five years, according to the software’s developer Darmiyan.

Described as a virtual microscope, the BrainSee prognostic program could be implemented before a positron emission tomography (PET) scan, which requires injections of radioactive tracers, or instead of biopsies of cerebrospinal fluid, the company said.

“Our vision is to redefine brain health screening and monitoring standards and impact the lives of patients and their family members in a meaningful way,” Darmiyan...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Provider, Radiology, Technology
When AI Learns To Lie
Diving into Health IT Policy, Medicare Advantage, and AI in Healthcare
Is AI The Secret Weapon To Help Stop Cyber Attacks?
Inching towards AGI: How reasoning and deep research are expanding AI from statistical prediction to structured problem-solving
How the U.S. is losing ground to China in nuclear fusion, as AI power needs surge

Share This Article